** Shares of drug developer CervoMed CRVO.O rise 4.4% to $6.44
** Brokerage Jones Research upgrades CRVO to "buy" rating from "hold", keeps PT of $15
** Upgrade follows CRVO's announcement of positive results from study of its drug, neflamapimod, in patients with dementia with Lewy bodies $(DLB)$ on Monday
** Data from study is boosting investor confidence, and we are seeing a more riskon approach heading into the next steps for netlamapimod in DLB patients - Jones Research
** DLB is a form of dementia caused by the accumulation of protein deposits called Lewy bodies in the brain's nerve cells
** Up to Wednesday's close, stock up 176.7% YTD
(Reporting by Juby Babu in Mexico City)
((Juby.Babu@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。